##common.pageHeaderLogo.altText##

Viewpoint

Vol. 151 No. 2122 (2021)

The importance of 18F-FDG cardiac PET/CT for the assessment of myocardial viability in ischaemic heart disease: A position paper endorsed by the Swiss Society of Nuclear Medicine (SGNM)

Cite this as:
Swiss Med Wkly. 2021;151:w20511
Published
05.06.2021

References

  1. Virani SS, Alonso A, Benjamin EJ, Bittencourt MS, Callaway CW, Carson AP, et al.; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2020 Update: A Report From the American Heart Association. Circulation. 2020;141(9):e139–596. doi:.https://doi.org/10.1161/CIR.0000000000000757
  2. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al.; Writing Group Members; American Heart Association Statistics Committee; Stroke Statistics Subcommittee. Executive Summary: Heart Disease and Stroke Statistics--2016 Update: A Report From the American Heart Association. Circulation. 2016;133(4):447–54. doi:.https://doi.org/10.1161/CIR.0000000000000366
  3. Rahimtoola SH. The hibernating myocardium. Am Heart J. 1989;117(1):211–21. doi:.https://doi.org/10.1016/0002-8703(89)90685-6
  4. Saltiel J, Lespérance J, Bourassa MG, Castonguay Y, Campeau L, Grondin P. Reversibily of left ventricular dysfunction following aorto-coronary by-pass grafts. Am J Roentgenol Radium Ther Nucl Med. 1970;110(4):739–46. doi:.https://doi.org/10.2214/ajr.110.4.739
  5. Horn HR, Teichholz LE, Cohn PF, Herman MV, Gorlin R. Augmentation of left ventricular contraction pattern in coronary artery disease by an inotropic catecholamine. The epinephrine ventriculogram. Circulation. 1974;49(6):1063–71. doi:.https://doi.org/10.1161/01.CIR.49.6.1063
  6. Allman KC. Noninvasive assessment myocardial viability: current status and future directions. J Nucl Cardiol. 2013;20(4):618–37, quiz 638–9. doi:.https://doi.org/10.1007/s12350-013-9737-8
  7. Thijssen VL, Borgers M, Lenders MH, Ramaekers FC, Suzuki G, Palka B, et al. Temporal and spatial variations in structural protein expression during the progression from stunned to hibernating myocardium. Circulation. 2004;110(21):3313–21. doi:.https://doi.org/10.1161/01.CIR.0000147826.13480.99
  8. Opie LH. Myocardial ischemia--metabolic pathways and implications of increased glycolysis. Cardiovasc Drugs Ther. 1990;4(S4, Suppl 4):777–90. doi:.https://doi.org/10.1007/BF00051275
  9. Gunning MG, Kaprielian RR, Pepper J, Pennell DJ, Sheppard MN, Severs NJ, et al. The histology of viable and hibernating myocardium in relation to imaging characteristics. J Am Coll Cardiol. 2002;39(3):428–35. doi:.https://doi.org/10.1016/S0735-1097(01)01766-1
  10. Elsässer A, Schlepper M, Klövekorn WP, Cai WJ, Zimmermann R, Müller KD, et al. Hibernating myocardium: an incomplete adaptation to ischemia. Circulation. 1997;96(9):2920–31. doi:.https://doi.org/10.1161/01.CIR.96.9.2920
  11. Kim SJ, Peppas A, Hong SK, Yang G, Huang Y, Diaz G, et al. Persistent stunning induces myocardial hibernation and protection: flow/function and metabolic mechanisms. Circ Res. 2003;92(11):1233–9. doi:.https://doi.org/10.1161/01.RES.0000076892.18394.B6
  12. Beanlands RS, Hendry PJ, Masters RG, deKemp RA, Woodend K, Ruddy TD. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging. Circulation. 1998;98(19, Suppl):II51–6.
  13. Page BJ, Banas MD, Suzuki G, Weil BR, Young RF, Fallavollita JA, et al. Revascularization of chronic hibernating myocardium stimulates myocyte proliferation and partially reverses chronic adaptations to ischemia. J Am Coll Cardiol. 2015;65(7):684–97. doi:.https://doi.org/10.1016/j.jacc.2014.11.040
  14. Dilsizian V, Bacharach SL, Beanlands RS, Bergmann SR, Delbeke D, Dorbala S, et al. ASNC imaging guidelines/SNMMI procedure standard for positron emission tomography (PET) nuclear cardiology procedures. J Nucl Cardiol. 2016;23(5):1187–226. doi:.https://doi.org/10.1007/s12350-016-0522-3
  15. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32(7):375–410. doi:.https://doi.org/10.1016/j.cpcardiol.2007.04.001
  16. Bax JJ, Poldermans D, Elhendy A, Boersma E, Rahimtoola SH. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr Probl Cardiol. 2001;26(2):147–81. doi:.https://doi.org/10.1067/mcd.2001.109973
  17. Beanlands RS, Nichol G, Huszti E, Humen D, Racine N, Freeman M, et al.; PARR-2 Investigators. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol. 2007;50(20):2002–12. doi:.https://doi.org/10.1016/j.jacc.2007.09.006
  18. Mc Ardle B, Shukla T, Nichol G, deKemp RA, Bernick J, Guo A, et al.; PARR-2 Investigators. Long-Term Follow-Up of Outcomes With F-18-Fluorodeoxyglucose Positron Emission Tomography Imaging-Assisted Management of Patients With Severe Left Ventricular Dysfunction Secondary to Coronary Disease. Circ Cardiovasc Imaging. 2016;9(9):e004331. doi:.https://doi.org/10.1161/CIRCIMAGING.115.004331
  19. D’Egidio G, Nichol G, Williams KA, Guo A, Garrard L, deKemp R, et al.; PARR-2 Investigators. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging. 2009;2(9):1060–8. doi:.https://doi.org/10.1016/j.jcmg.2009.02.017
  20. Ling LF, Marwick TH, Flores DR, Jaber WA, Brunken RC, Cerqueira MD, et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging. 2013;6(3):363–72. doi:.https://doi.org/10.1161/CIRCIMAGING.112.000138
  21. Abraham A, Nichol G, Williams KA, Guo A, deKemp RA, Garrard L, et al.; PARR 2 Investigators. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial. J Nucl Med. 2010;51(4):567–74. doi:.https://doi.org/10.2967/jnumed.109.065938
  22. Hartikainen J, Hassinen I, Hedman A, Kivelä A, Saraste A, Knuuti J, et al. Adenoviral intramyocardial VEGF-DΔNΔC gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up. Eur Heart J. 2017;38(33):2547–55. doi:.https://doi.org/10.1093/eurheartj/ehx352
  23. Beanlands RS, Ruddy TD, deKemp RA, Iwanochko RM, Coates G, Freeman M, et al.; PARR Investigators. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol. 2002;40(10):1735–43. doi:.https://doi.org/10.1016/S0735-1097(02)02489-0
  24. Jacklin PB, Barrington SF, Roxburgh JC, Jackson G, Sariklis D, West PA, et al. Cost-effectiveness of preoperative positron emission tomography in ischemic heart disease. Ann Thorac Surg. 2002;73(5):1403–9, discussion 1410. doi:.https://doi.org/10.1016/S0003-4975(02)03459-8
  25. Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343(20):1445–53. doi:.https://doi.org/10.1056/NEJM200011163432003
  26. Garcia MJ, Kwong RY, Scherrer-Crosbie M, Taub CC, Blankstein R, Lima J, et al.; American Heart Association Council on Cardiovascular Radiology and Intervention and Council on Clinical Cardiology. State of the Art: Imaging for Myocardial Viability: A Scientific Statement From the American Heart Association. Circ Cardiovasc Imaging. 2020;13(7):e000053. doi:.https://doi.org/10.1161/HCI.0000000000000053
  27. Schmidt M, Voth E, Schneider CA, Theissen P, Wagner R, Baer FM, et al. F-18-FDG uptake is a reliable predictory of functional recovery of akinetic but viable infarct regions as defined by magnetic resonance imaging before and after revascularization. Magn Reson Imaging. 2004;22(2):229–36. doi:.https://doi.org/10.1016/j.mri.2003.07.006
  28. Rischpler C, Langwieser N, Souvatzoglou M, Batrice A, van Marwick S, Snajberk J, et al. PET/MRI early after myocardial infarction: evaluation of viability with late gadolinium enhancement transmurality vs. 18F-FDG uptake. Eur Heart J Cardiovasc Imaging. 2015;16(6):661–9. doi:.https://doi.org/10.1093/ehjci/jeu317
  29. Kühl HP, Lipke CS, Krombach GA, Katoh M, Battenberg TF, Nowak B, et al. Assessment of reversible myocardial dysfunction in chronic ischaemic heart disease: comparison of contrast-enhanced cardiovascular magnetic resonance and a combined positron emission tomography-single photon emission computed tomography imaging protocol. Eur Heart J. 2006;27(7):846–53. doi:.https://doi.org/10.1093/eurheartj/ehi747
  30. Patterson RE, Sigman SR, O’Donnell RE, Eisner RL. Viability assessment with MRI is superior to FDG-PET for viability: Con. J Nucl Cardiol. 2010;17(2):298–309. doi:.https://doi.org/10.1007/s12350-010-9209-3
  31. Maddahi J. Viability assessment with MRI is superior to FDG-PET for viability: Pro. J Nucl Cardiol. 2010;17(2):292–7. doi:.https://doi.org/10.1007/s12350-010-9201-y
  32. Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al.; ESC Scientific Document Group. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019;40(2):87–165. doi:.https://doi.org/10.1093/eurheartj/ehy394
  33. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al.; ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129–200. doi:.https://doi.org/10.1093/eurheartj/ehw128
  34. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39(7):1151–8. doi:.https://doi.org/10.1016/S0735-1097(02)01726-6
  35. Zanzonico P, Dauer L, Strauss HW. Radiobiology in Cardiovascular Imaging. JACC Cardiovasc Imaging. 2016;9(12):1446–61. doi:.https://doi.org/10.1016/j.jcmg.2016.09.012